Ticlopidine

Platelet Aggregation Inhibitor — BLOOD AND BLOOD FORMING ORGANS

Key facts

Ticlopidine is an ofm drug in the Platelet Aggregation Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1991. DrugCentral lists 14 molecular targets, including ADRA2B, ADRA2A and ADRA2C. Recorded indications include Cerebrovascular Occlusion, Percutaneous coronary intervention, Prevention of Cerebral Thrombosis and Subacute Stent Thrombosis Prevention.

• Approval status: ofm (first approved 1991 by the FDA).
• Drug class: Platelet Aggregation Inhibitor.
• Molecular targets: ADRA2B, ADRA2A, ADRA2C and SIGMAR1 (14 listed in DrugCentral).
• Indications: Cerebrovascular Occlusion, Percutaneous coronary intervention, Prevention of Cerebral Thrombosis and Subacute Stent Thrombosis Prevention.
• ATC code: B01AC05 (Platelet aggregation inhibitors excl. heparin).
• Molecular formula: C14H14ClNS; molecular weight 263.78 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (4)

• Cerebrovascular Occlusion
• Percutaneous coronary intervention
• Prevention of Cerebral Thrombosis
• Subacute Stent Thrombosis Prevention

Contraindications (18)

• Acute nephropathy
• Arterial aneurysm
• Ascorbic acid deficiency
• Bleeding
• Blood coagulation disorder
• Cerebral hemorrhage
• Congenital hypoplastic anemia
• Gastrointestinal hemorrhage
• Gastrointestinal ulcer
• Hyperlipidemia
• Leukemia, disease
• Lumbar puncture
• Neutropenic disorder
• Obstruction of bile duct
• Procedure on central nervous system
• Surgical procedure
• Thrombocytopenic disorder
• Thrombotic thrombocytopenic purpura

Mechanism & targets

• Established pharmacologic class: Platelet Aggregation Inhibitor

Molecular targets (14)

Target	Gene	Action	Activity
Alpha-2B adrenergic receptor	ADRA2B	unknown	Ki 6.86
Alpha-2A adrenergic receptor	ADRA2A	unknown	Ki 6.84
Alpha-2C adrenergic receptor	ADRA2C	unknown	Ki 6.77
Sigma non-opioid intracellular receptor 1	SIGMAR1	unknown	Ki 6.75
Cytochrome P450 2A6	CYP2A6	unknown	Ki 6.70
Cytochrome P450 2B6	CYP2B6	inhibitor	IC50 6.70
Cytochrome P450 2C19	CYP2C19	unknown	IC50 6.17
Membrane-associated progesterone receptor component 1	Pgrmc1	unknown	Ki 5.70
Cytochrome P450 2D6	CYP2D6	unknown	IC50 5.20
Prostaglandin G/H synthase 2	PTGS2	unknown	IC50 4.33
Bile salt export pump	Abcb11	unknown	IC50 4.31
Prostaglandin G/H synthase 1	PTGS1	unknown	IC50 4.28
Bile salt export pump	ABCB11	unknown	IC50 4.13
P2Y purinoceptor 12	P2RY12	antagonist	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1991-10-31	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
B01AC05	BLOOD AND BLOOD FORMING ORGANS › ANTITHROMBOTIC AGENTS › ANTITHROMBOTIC AGENTS › Platelet aggregation inhibitors excl. heparin

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Drug interaction	140.0
Sopor	138.6
Melaena	82.0
Anaemia	65.3
Cerebral haemorrhage	63.5
Intentional self-injury	61.3
Hyperkalaemia	61.1
Hyponatraemic syndrome	57.0
Hyponatraemia	56.7
Drug abuse	50.1
Slow speech	49.0
Labelled drug-drug interaction medication error	47.2

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Ticlopidine is on its molecule page.

• Molecular formula: C₁₄H₁₄ClNS
• Molecular weight: 263.78 g/mol
• CAS number: 55142-85-3
• InChIKey: PHWBOXQYWZNQIN-UHFFFAOYSA-N
• PubChem CID: 5472

ClC1=C(CN2CCC3=C(C2)C=CS3)C=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ticlopidine used for?

DrugCentral lists the following indications for Ticlopidine: Cerebrovascular Occlusion, Percutaneous coronary intervention, Prevention of Cerebral Thrombosis and Subacute Stent Thrombosis Prevention.

How does Ticlopidine work?

Its molecular targets in DrugCentral include ADRA2B, ADRA2A, ADRA2C and SIGMAR1.

When was Ticlopidine first approved?

Ticlopidine was first approved by the FDA in 1991.

What drug class does Ticlopidine belong to?

Ticlopidine is in the Platelet Aggregation Inhibitor class.

What is the chemical formula of Ticlopidine?

Ticlopidine has the molecular formula C14H14ClNS and a molecular weight of 263.78 g/mol.

Sources

• DrugCentral drug card 2657 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1717 — compound record and bioactivity
• PubChem CID 5472 — chemical identifiers
• DrugBank DB00208 — drug record
• FDA UNII OM90ZUW7M1 — substance identity
• DailyMed: FDA labels for Ticlopidine — current prescribing information (label search)
• UniProt P18089 (ADRA2B) — target protein
• UniProt P08913 (ADRA2A) — target protein
• UniProt P18825 (ADRA2C) — target protein
• UniProt Q99720 (SIGMAR1) — target protein
• UniProt P11509 (CYP2A6) — target protein
• UniProt P20813 (CYP2B6) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.